TP2 Micronutrient Testing TP2 research

Since TP2 micronutrients show an effect on cancer treatment, which has been confirmed by the testimonies of many people, it was decided to conduct laboratory tests to determine the effect of the product on cancer cells.

Research Unit

Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences Laboratory of Experimental Anticancer Therapy

Method of conducting the study

The study was performed in vitro (under laboratory conditions) on five human cancer cell lines: lung cancer, prostate cancer, breast cancer, ovarian cancer, colorectal cancer.

Full report

Research Summary

Based on the studies that were carried out, it appears that the TP2 formulation showed about 2-2.5 times higher activity, compared to the TP1 formulation, in inhibiting the growth of cancer cells (under laboratory conditions). The higher activity of TP2 was related to the presence of iron and copper ions in this preparation.

Results for TP2

The TP2 preparation was applied directly to the cancer cells at various concentrations (dilutions). The number of cells after treatment with the test formulations was compared to the number of control cells (treated with nothing) and was determined as % of living cells compared to 100% treated control cells.

Prostate cancer (PC-3 human prostate cancer cells)

The TP2 formulation at the highest dilution used, 1:400, inhibited prostate cancer cells by about 78% (under laboratory conditions), meaning that live prostate cancer cells remained only about 22% compared to control cells.

Colorectal cancer (HT-29 human colon cancer cells)

The TP2 formulation at the highest dilution used, 1:400, inhibited colorectal cancer tumor cells by about 97% (under laboratory conditions), meaning that live colorectal cancer cells were left with only about 3% compared to control cells.

Ovarian cancer (A2780 human ovarian cancer cells)

The TP2 formulation inhibited lung cancer and breast cancer tumor cells by about 96%, meaning there were only about 4% of living lung cancer and breast cancer tumor cells left.

Lung cancer (A549 human lung cancer cells)

The TP2 formulation at the highest dilution used, 1:400, inhibited lung cancer tumor cells by about 96% (under laboratory conditions), meaning that live lung cancer tumor cells remained only about 4% compared to control cells.

Breast cancer (MCF-7 human breast cancer cells)

The TP2 formulation at the highest dilution used, 1:400, inhibited breast cancer tumor cells by about 96% (under laboratory conditions), meaning that live breast cancer tumor cells remained only about 4% compared to control cells.

Expert opinions

Dr. Tadeusz Podbielski began his work and research on TP preparations in 1945. Below are the opinions of other experts and institutions after the research and verification of TP preparations.

Academy of Medicine in Poznań

Academy of Medicine in Poznań referring to the determinations carried out in Katadra of Co, Mg, Zn ions in the TP1 preparation and Co, Mg, Zn, Cu, Fe ions in the TP2 preparation, developed by Dr. Podbielski, I state that the professional literature does not indicate that this composition and the dosage method can pose a threat to human health. (Prof. Dr. Jan Pawlaczyk, Academy of Medicine in Poznań, April 28, 2003)

Institute of Food and Nutrition

The Food and Nutrition Institute in response to a letter of opinion on the micronutrient products TP1 and TP2 by Dr. Tadeusz Podbielski: the institute has no objections to the composition of the above-mentioned products and the proposed dosage. (Deputy Director for Food Safety Dr. n. med. Lucjan Szponar, Prof. Dr. Aleksander Szczygiel Institute of Food and Nutrition, Warsaw, December 5, 2003)

Chief Sanitary Inspectorate

The Chief Sanitary Inspectorate kindly informs: the above-mentioned products received a positive opinion of the Food and Nutrition Institute dated December 5, 2003 and can be marketed in Poland. (Director Maria Stachowiak, Chief Sanitary Inspectorate, February 17, 2004.